E-52862
E-52862 is a selective sigma receptor agonist that is currently under investigation for its potential use in the treatment of pain. It was developed by the Spanish pharmaceutical company Esteve.
Pharmacology[edit | edit source]
E-52862 interacts with sigma receptors, specifically the sigma-1 receptor. Sigma receptors are a unique class of intracellular receptors that have been implicated in a variety of biological functions, including neuroplasticity, neuroprotection, and the modulation of neurotransmission.
Clinical Trials[edit | edit source]
E-52862 has undergone Phase I and Phase II clinical trials for the treatment of pain. The results of these trials have shown that E-52862 is well-tolerated and has a favorable safety profile. Further studies are needed to fully understand the therapeutic potential of this drug.
See Also[edit | edit source]
References[edit | edit source]
E-52862 Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD